查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284279

到 2028 年的基因組編輯市場預測——按產品/服務、技術、應用、最終用戶和地區進行的全球分析

Genome Editing Market Forecasts to 2028 - Global Analysis By Product & Service, By Technology, By Application, By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球基因組編輯市場規模將達到 61 億美元，預計到 2028 年將達到 185 億美元，預測期內復合年增長率為 20.2%。生長。

基因編輯是使用儀器和過程，通過對基因的 DNA 序列進行高度特異性的改變，從而顯著改變生物體的遺傳藍圖。 與將遺傳物質隨機加入宿主基因組的基因工程不同，基因編輯旨在修改特定的目標區域。

根據國家轉化科學促進中心 2022 年 6 月的更新，美國國立衛生研究院 (NIH) 的體細胞基因組編輯 (SCGE) 計劃向美國和加拿大研究人員授予了 24 項額外資助。

市場動態：

驅動程序

基因組編輯的發展

最近的發展大大提高了基因組編輯能力，可以修改各種細胞類型和模型物種中的獨特基因序列。 特別是在腫瘤學測試中，基因組編輯有可能顯著改變診斷工具。 基因組工程已被各國政府和大學等主要研究機構所採用。 然而，基因編輯技術的快速發展正在使研究機構向臨床和診斷機構發生重大轉變。

約束

設備成本高

基因組儀器價格昂貴，由於其最先進的功能和特性，平均價值在 1000 萬美元到 2000 萬美元之間。 由於製藥公司和實驗室需要大量的系統，購買多台基因組儀器的資本投資是巨大的。 中小型藥企和實驗室大量投資基因組儀器是不切實際的。

機會

基因組編輯在個性化醫療中的廣泛應用

隨著個性化醫療領域的發展，基因組編輯市場參與者應該看到機遇。 在個性化醫療的幫助下，從業者可以確定患者的確切需求，並據此開出藥物和治療方案。 由於個性化醫療具有節省成本、提高患者依從性、及早發現疾病和改善治療的潛力，因此在全球範圍內的使用正在增長。

威脅

CRISPR 技術的脫靶效應

CRISPR-Cas9 的脫靶結果備受關注。 因為 Cas9 會產生雙鏈斷裂，脫靶核酸□活性會修飾這些基因並導致腫瘤發生。 CRISPR-Cas9 可以容忍靶標中的一到三個錯配，並可能導致脫靶核酸□活性。 主要關注的是高頻率的脫靶活動 (50%)，這是指在預期的目標站點之外進行的修改。 例如，CRISPR 可以激活致癌基因或靶向抑癌基因。 由於這種不良影響，許多組織臨床研究的公司都遇到了問題。 臨床試驗已被取消，監管機構呼籲進行更多研究以提高這種方法的安全性。

COVID-19 的影響：

COVID-19 正在對基因組編輯市場產生積極影響。 COVID-19 流行病正在增加全球醫療保健系統的壓力。 由於 COVID-19 大流行，大型製藥和生物技術公司正在增加對疫苗研發和基因組編輯市場參與者的投資。 由於對疫苗接種和潛在抗病毒藥物的需求不斷增長，基因組編輯和工程技術處於科學研究的前沿。 此外，不僅對基因組編輯市場，而且對其他醫療保健服務也產生了一定的影響。 發現 COVID-19 後，許多研究人員開始研究這種獨特的病毒及其產生的疾病。

在預測期內，成簇的規則間隔子短單臂重複 (CRISPR) 片段預計將是最大的

由於政府在免疫、醫療技術、藥物和小工具開發方面的資金增加和努力，成簇常規間隔子短鍊長重複序列 (CRISPR) 片段預計在此期間將適度增長。 2021 年 1 月發表在《新英格蘭醫學雜誌》上的一項題為“針對鐮狀細胞病和地中海貧血的 CRISPR-Cas9 基因編輯”的研究發現了兩例遺傳病：TDT（地中海貧血）患者和 SCD（CRISPR-Cas9-基於基因編輯的技術正在鐮狀細胞病患者中進行測試。 在給予 CTX001 後的第二年，兩名患者的胎兒血紅蛋白水平早期、顯著和長期增加，胰液□99%。 因此，由於 CRISPR 技術在治療鐮狀細胞病和 β-地中海貧血等疾病中的應用，預計在預測期內需求將增長。

細胞系編輯領域有望在預測期內見證最高的複合年增長率

隨著幹細胞研究越來越多地使用細胞系工程，細胞系編輯領域預計將實現長期盈利增長。 細胞系工程廣泛用於誘導多能幹細胞 (iPSC)，這些幹細胞通過快速改進幫助改變細胞的遺傳物質。 此外，鋅指核酸□ (ZFN)、CRISPR/Cas 和 TALEN 等先進的基因編輯方法使細胞編輯變得經濟實惠且可行。

份額最大的地區

由於生物技術和製藥行業的強勁發展趨勢，北美在全球基因組編輯市場佔據主導地位。 在預測期內，基因組編輯技術的進步、產品批准的增加以及研發程序的擴大等因素預計將推動市場的擴張。 然而，2021 年 3 月，美國食品和藥物管理局宣布，來自加州大學 (UC)、舊金山分校、加州大學伯克利分校和加州大學洛杉磯分校的研究人員將使用患者的造血幹細胞來測試針對鐮狀細胞病患者的基因校正療法細胞疾病。我們同意共同啟動一項早期、首次人體臨床試驗。

複合年增長率最高的地區：

由於基因療法的進步、轉基因作物消費量的增加以及獲得研究資金的便利，為基因編輯提供工具和服務，北美將在預測期內保持最高的複合年增長率。我們相信它將繼續成為對我們的業務做出重大貢獻。 美國也在北美市場佔據主導地位，這主要是由於公共和私人對基因組研究的資助不斷增加。 此外，北美基因組編輯市場受到美國和加拿大罕見疾病流行率上升的推動。 根據美國國立衛生研究院 (NIH) 的數據，超過 7,000 種罕見病影響著 25 至 3000 萬美國人。 根據這一統計數據，十分之一的美國人患有罕見病。 因此，這些國家採用新的 DNA 編輯方法是由於對提供有效藥物的需求日益增長。

主要發展：

2022 年 5 月，英國議會出台了允許推出基因編輯產品的立法。 遺傳技術（精準育種）法案旨在使企業、農民和消費者受益。 該法案目前正處於眾議院的報告階段。

2022 年 2 月，Integrated DNA Technologies 宣布推出 Alt-R HDR Donor Blocks，這是一種提高同源定向修復 (HDR) 率的改進解決方案。 Alt-R HDR Donor Blocks 是 IDT 完整的 Alt-R CRISPR 基因組編輯解決方案組合的最新成員。

2022 年 2 月，Intellia Therapeutics, Inc. 和 Regeneron Pharmaceuticals, Inc. 宣布了 NTLA-2001（針對轉甲狀腺素蛋白 (Attr) 澱粉樣變性的研究性 Crispr 療法）的第一項正在進行的研究，這是領先的體內基因組編輯候選藥物。提供了分階段臨床試驗的中期數據。

2022 年 1 月，CRISPR Therapeutics AG 宣布與 Capsida Biotherapeutics Inc. 建立戰略合作夥伴關係，以利用 CRISPR/Cas9 技術開髮用於治療各種疾病的新型基因療法。Did。 根據協議，CRISPR Therapeutics 將提供基因組編輯專業知識，Capsida 將提供腺相關病毒（AAV）遞送技術。

這份報告提供了什麼

  • 區域和國家/地區細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球基因組編輯市場：按產品和服務分類

  • 試劑和耗材
  • 服務
  • 軟件和系統
  • 細胞系
  • 其他產品和服務

第 6 章全球基因組編輯市場：按技術分類

  • 成簇規則間隔的短回文重複序列 (CRISPR)
  • 鋅指核酸□ (ZFN)
  • 轉錄激活因子樣效應核酸□ (TALEN)
  • 反義
  • 限制□
  • 其他技術

第 7 章全球基因組編輯市場：按應用

  • 編輯細胞系
  • 基因工程
    • 植物基因工程
    • 動物基因工程
  • 藥物發現和開發
  • 診斷應用
  • 微生物基因工程
  • 基因療法
  • 其他用途

第 8 章全球基因組編輯市場：按最終用戶分類

  • 臨床研究機構
  • 學術機構和政府研究機構
  • 製藥和生物技術公司
  • 委託研究機構
  • 其他最終用戶

第 9 章。全球基因組編輯市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Agilent Technologies Inc.
  • AstraZeneca
  • Beam Therapeutics
  • Bluebird Bio
  • Caribou Biosciences, Inc
  • Cellectis S.A.
  • Cibus, Recombinetics, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine Inc.
  • Egenesis Inc.
  • GenScript Biotech Corporation
  • GenScript USA Inc.
  • Horizon Discovery Group plc
  • Integrated DNA Technologies Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd
  • Merck KGaA
  • New England Biolabs Inc.
  • Origene Technologies Inc.
  • Precision BioSciences Inc.
  • Sangamo Therapeutics Inc.
  • Takara Bio Inc.
  • Tecan Life Sciences
  • Thermo Fisher Scientific Inc.
  • Transposagen Biopharmaceuticals Inc.
Product Code: SMRC23111

According to Stratistics MRC, the Global Genome Editing Market is accounted for $6.1 billion in 2022 and is expected to reach $18.5 billion by 2028 growing at a CAGR of 20.2% during the forecast period. Gene editing is the use of instruments and processes that significantly change the genetic blueprints of a living thing by making extremely particular alterations to the DNA sequence of a gene. Gene editing strives to modify particular target regions, as opposed to genetic engineering, which randomly combines genetic material into a host genome.

According to the National Center for Advancing Translational Sciences updates form June 2022, the Somatic Cell Genome Editing (SCGE) Program at the National Institutes of Health (NIH) has awarded 24 more grants to researchers across the United States and Canada.

Market Dynamics:

Driver:

Developments in genome editing

Recent developments have substantially improved genome editing capabilities, enabling the alteration of unique gene sequences in a variety of cell types and model species. In particular, for oncology tests, genome engineering has developed into a potentially game-changing diagnostic tool. Genome engineering was previously used by major research institutions, including those affiliated with the government and universities. This significant movement away from academics and into clinical and diagnostic facilities is primarily driven by the rapid advancement of gene editing technology.

Restraint:

High equipment costs

Because genomic instruments have cutting-edge features and functions, they are more expensive, with costs averaging between USD 10 and USD 20 million. As many of these systems are needed by pharmaceutical businesses and research labs, their capital expenditure to acquire several genomic equipment is very significant. It is not practical for small and medium-sized pharmaceutical corporations and research labs to invest substantially in numerous genomics devices.

Opportunity:

Extensive use of genome editing in personalized medicine

Players in the genome editing market should have opportunities as the field of customized medicine grows. With the aid of personalized medicine, practitioners may identify a patient's precise needs and then prescribe medications and treatments in response. Due to its potential for cost reductions, better patient compliance, early disease identification, and therapy improvement, the use of customized medicine is expanding globally.

Threat:

Off-target effects of CRISPR technology

CRISPR-Cas9's off-target consequences are a significant concern. Any off-target nuclease activity may modify these genes and result in oncogenesis since Cas9 generates double-stranded breaks. One to three mismatches in the target can be tolerated by CRISPR-Cas9, which can result in off-target nuclease activity. A significant concern is the high frequency of off-target activity (50%), which refers to alterations at locations other than the planned on-target site. For instance, CRISPR can activate the cancer-causing gene or target the tumor suppressor gene. Due to this undesirable effect, numerous companies that are organizing clinical studies have experienced problems. Clinical trials have been revoked, and regulatory authorities demand more studies to improve the safety of this procedure.

COVID-19 Impact:

COVID-19 has a favorable effect on the market for genome editing. The COVID-19 epidemic has increased the strain on healthcare systems around the world. Major pharmaceutical and biotechnology companies have increased their investments in vaccine R&D and market players for genome editing as a result of the COVID-19 pandemic. Due to the rising demand for vaccinations and potential antiviral medications, genome editing and engineering technologies are at the forefront of scientific research. Additionally, there has been a moderate impact on the market for genome editing as well as other healthcare services. Many researchers switched their attention to the investigation of this unique virus and the illness it produces after COVID-19 was originally identified.

The clustered regularly interspaced short palindromic repeats (CRISPR) segment is expected to be the largest during the forecast period

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) segment is expected to have moderate growth over the projected period because of increased government financing and initiatives to develop vaccinations, medical technology, pharmaceuticals, and gadgets. In two cases of inherited diseases-one in a patient with TDT (thalassemia) and the other in a patient with SCD (sickle cell disease)-CRISPR-Cas9-based gene editing is being tested, according to a study titled "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and -Thalassemia," published in the New England Journal of Medicine in January 2021. Both patients witnessed early, significant, and long-lasting increases in fetal hemoglobin levels with more than 99% pancellularity throughout the course of the following year after receiving CTX001. Therefore, it is anticipated that over the forecast period, demand for CRISPR technology will increase due to its use in treating diseases including sickle cell disease and beta-thalassemia.

The cell line editing segment is expected to have the highest CAGR during the forecast period

Due to the expanding use of cell line engineering in stem cell-based research, it is predicted that the cell line editing segment will have profitable growth over an extended period. Cell line engineering is widely used for induced pluripotent stem cells (iPSCs), which help to change the genetic material of the cells as a result of rapid improvements. Additionally, advanced gene editing methods, including zinc finger nucleases (ZFNs), CRISPR/Cas, and TALENs, have made cell editing affordable and feasible.

Region with largest share:

Due to the biotechnology and pharmaceutical industries' strong development trends, North America has acquired a monopoly on the global market for genome editing. During the anticipated period, it is predicted that factors including technological advancements in genome editing, rising product approvals, and expanding R&D procedures would accelerate market expansion. However, the United States Food and Drug Administration provided consent to researchers at the University of California (UC), San Francisco, UC Berkeley, and UC Los Angeles in March 2021 to jointly begin an early-phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells.

Region with highest CAGR:

Due to the advancement of gene therapy, growing consumption of genetically modified crops, and easy access to research funding, North America hold the highest CAGR over the forecasted period and will continue to make the largest contribution to businesses offering tools and services for gene editing. Additionally, the U.S. controls the majority of the market in North America, mostly as a result of increased public and private financing for genomics research. Furthermore, the market for genome editing in North America is being driven by the rising prevalence of rare illnesses in the United States and Canada. More than 7,000 rare diseases affect between 25 and 30 million Americans, according to the National Institutes of Health (NIH). According to this statistic, one in ten Americans has a rare disorder. As a result, the adoption of novel DNA editing methods in these nations is driven by the growing need to provide effective medications.

Key players in the market:

Some of the key players in Genome Editing market include Agilent Technologies Inc., AstraZeneca, Beam Therapeutics, Bluebird Bio, Caribou Biosciences, Inc, Cellectis S.A., Cibus, Recombinetics, Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Egenesis Inc., GenScript Biotech Corporation, GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies Inc., Intellia Therapeutics, Inc., Lonza Group Ltd, Merck KGaA, New England Biolabs Inc., Origene Technologies Inc., Precision BioSciences Inc., Sangamo Therapeutics Inc., Takara Bio Inc., Tecan Life Sciences , Thermo Fisher Scientific Inc. and Transposagen Biopharmaceuticals Inc.

Key Developments:

In May 2022, the English parliament introduced a Bill that would enable the release of genetically edited products. The Genetic Technology (Precision Breeding) Bill aims to benefit companies, farmers, and consumers. The bill is currently under the report stage in the House of Commons.

In February 2022, Integrated DNA Technologies unveiled Alt-R HDR Donor Blocks, an improved solution for increasing homology-directed repair (HDR) rates. Alt-R HDR Donor Blocks are the latest addition to IDT's complete portfolio of Alt-R CRISPR genome editing solutions.

In February 2022, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).

In January 2022, CRISPR Therapeutics AG announced a strategic partnership with Capsida Biotherapeutics Inc. to develop new gene therapies using the CRISPR/Cas9 technology for the treatment of various diseases. Under the agreement, CRISPR Therapeutics will provide its genome editing expertise, while Capsida will contribute its adeno-associated virus (AAV) delivery technology.

Product & Services Covered:

  • Reagents & Consumables
  • Services
  • Software & Systems
  • Cell Lines
  • Other Product & Services

Technologies Covered:

  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • Zinc Finger Nuclease (ZFN)
  • Transcription Activator-Like Effector Nuclease (TALEN)
  • Antisense
  • Restriction Enzymes
  • Other Technologies

Applications Covered:

  • Cell Line Editing
  • Genetic Engineering
  • Drug Discovery & Development
  • Diagnostic Applications
  • Microorganisms Genetic Engineering
  • Gene Therapy
  • Other Applications

End Users Covered:

  • Clinical Research Organizations
  • Academics & Government Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organization
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genome Editing Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Reagents & Consumables
  • 5.3 Services
  • 5.4 Software & Systems
  • 5.5 Cell Lines
  • 5.6 Other Product & Services

6 Global Genome Editing Market, By Technology

  • 6.1 Introduction
  • 6.2 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • 6.3 Zinc Finger Nuclease (ZFN)
  • 6.4 Transcription Activator-Like Effector Nuclease (TALEN)
  • 6.5 Antisense
  • 6.6 Restriction Enzymes
  • 6.7 Other Technologies

7 Global Genome Editing Market, By Application

  • 7.1 Introduction
  • 7.2 Cell Line Editing
  • 7.3 Genetic Engineering
    • 7.3.1 Plant Genetic Engineering
    • 7.3.2 Animal Genetic Engineering
  • 7.4 Drug Discovery & Development
  • 7.5 Diagnostic Applications
  • 7.6 Microorganisms Genetic Engineering
  • 7.7 Gene Therapy
  • 7.8 Other Applications

8 Global Genome Editing Market, By End User

  • 8.1 Introduction
  • 8.2 Clinical Research Organizations
  • 8.3 Academics & Government Research Institutes
  • 8.4 Pharmaceutical & Biotechnology Companies
  • 8.5 Contract Research Organization
  • 8.6 Other End Users

9 Global Genome Editing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Agilent Technologies Inc.
  • 11.2 AstraZeneca
  • 11.3 Beam Therapeutics
  • 11.4 Bluebird Bio
  • 11.5 Caribou Biosciences, Inc
  • 11.6 Cellectis S.A.
  • 11.7 Cibus, Recombinetics, Inc.
  • 11.8 CRISPR Therapeutics AG
  • 11.9 Editas Medicine Inc.
  • 11.10 Egenesis Inc.
  • 11.11 GenScript Biotech Corporation
  • 11.12 GenScript USA Inc.
  • 11.13 Horizon Discovery Group plc
  • 11.14 Integrated DNA Technologies Inc.
  • 11.15 Intellia Therapeutics, Inc.
  • 11.16 Lonza Group Ltd
  • 11.17 Merck KGaA
  • 11.18 New England Biolabs Inc.
  • 11.19 Origene Technologies Inc.
  • 11.20 Precision BioSciences Inc.
  • 11.21 Sangamo Therapeutics Inc.
  • 11.22 Takara Bio Inc.
  • 11.23 Tecan Life Sciences
  • 11.24 Thermo Fisher Scientific Inc.
  • 11.25 Transposagen Biopharmaceuticals Inc.

List of Tables

  • Table 1 Global Genome Editing Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Genome Editing Market Outlook, By Product & Service (2020-2028) ($MN)
  • Table 3 Global Genome Editing Market Outlook, By Reagents & Consumables (2020-2028) ($MN)
  • Table 4 Global Genome Editing Market Outlook, By Services (2020-2028) ($MN)
  • Table 5 Global Genome Editing Market Outlook, By Software & Systems (2020-2028) ($MN)
  • Table 6 Global Genome Editing Market Outlook, By Cell Lines (2020-2028) ($MN)
  • Table 7 Global Genome Editing Market Outlook, By Other Product & Services (2020-2028) ($MN)
  • Table 8 Global Genome Editing Market Outlook, By Technology (2020-2028) ($MN)
  • Table 9 Global Genome Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2020-2028) ($MN)
  • Table 10 Global Genome Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2020-2028) ($MN)
  • Table 11 Global Genome Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (TALEN) (2020-2028) ($MN)
  • Table 12 Global Genome Editing Market Outlook, By Antisense (2020-2028) ($MN)
  • Table 13 Global Genome Editing Market Outlook, By Restriction Enzymes (2020-2028) ($MN)
  • Table 14 Global Genome Editing Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 15 Global Genome Editing Market Outlook, By Application (2020-2028) ($MN)
  • Table 16 Global Genome Editing Market Outlook, By Cell Line Editing (2020-2028) ($MN)
  • Table 17 Global Genome Editing Market Outlook, By Genetic Engineering (2020-2028) ($MN)
  • Table 18 Global Genome Editing Market Outlook, By Plant Genetic Engineering (2020-2028) ($MN)
  • Table 19 Global Genome Editing Market Outlook, By Animal Genetic Engineering (2020-2028) ($MN)
  • Table 20 Global Genome Editing Market Outlook, By Drug Discovery & Development (2020-2028) ($MN)
  • Table 21 Global Genome Editing Market Outlook, By Diagnostic Applications (2020-2028) ($MN)
  • Table 22 Global Genome Editing Market Outlook, By Microorganisms Genetic Engineering (2020-2028) ($MN)
  • Table 23 Global Genome Editing Market Outlook, By Gene Therapy (2020-2028) ($MN)
  • Table 24 Global Genome Editing Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 25 Global Genome Editing Market Outlook, By End User (2020-2028) ($MN)
  • Table 26 Global Genome Editing Market Outlook, By Clinical Research Organizations (2020-2028) ($MN)
  • Table 27 Global Genome Editing Market Outlook, By Academics & Government Research Institutes (2020-2028) ($MN)
  • Table 28 Global Genome Editing Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 29 Global Genome Editing Market Outlook, By Contract Research Organization (2020-2028) ($MN)
  • Table 30 Global Genome Editing Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.